AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05216744
Drug: Ceftriaxone 1000mg + doxycycline 100 mg
RxNorm normalized name: ceftriaxone 1000 MG
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
Trial: NCT05216744
Drug: Cefixime 800mg + doxycycline 100 mg
RxNorm normalized name: (-)-cefixim
DrugBank: Cefixime (DB00671)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study comparing the effectiveness of two combination regimens in the treatment of gonorrhea and chlamydia, including regimen A (100mg doxycycline orally twice a day for 7 days + 1 dose of 1000mg ceftriaxone intravenously) and regimen B (100mg doxycycline). orally for 7 days + 1 oral dose of 800mg cefixime)
Trial: NCT05989828
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05724511
Drug: MIYAIRI 588
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the 3 months intervention, each subjects take 1g/package with meal, and 3 packages/day.
Trial: NCT04849559
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsule
Trial: NCT04776655
Drug: Calcium levofolinate
RxNorm normalized name: calcium levofolinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
Trial: NCT05613465
Drug: Codonopsis
RxNorm normalized name: CODONOPSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codonopsis pilosula Nnannf is oral liquid, which has been approved for listing
Trial: NCT05613465
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is packaged in the same package as the drug
Trial: NCT05696093
Drug: standard antibiotic therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of standard antibiotic therapy for enterobacterial VAP
Trial: NCT04431960
Drug: blackcurrant (BC) extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
Trial: NCT04994002
Drug: CERC-006
RxNorm normalized name: CERCIS SILIQUASTRUM WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT06650371
Drug: Fentanyl infusion
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: opioid based anesthesia analgesia will be offered by fentanyl in induction and maintenance according to Ideal Body Weight (IBW).
Trial: NCT05593562
Drug: SPH3127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 100 mg \[14 c\] SPH3127 mixed suspension
Trial: NCT06329895
Drug: BAY2927088
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT06329895
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral administration.
Trial: NCT05385783
Drug: CYB003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYB003 is a synthetic psilocybin analog.
Trial: NCT05385783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04822701
Drug: Placebo intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous
Trial: NCT04822701
Drug: Placebo inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaled
Trial: NCT05121038
Drug: Folfirinox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order.~All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).~* Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then~* Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.~* Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.~then~• Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home.
Trial: NCT05651373
Drug: CertolizumabPegol injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg, iH,q2w, once two weeks (q2w) prescribed from the beginning and adjusted due to patient response.
Trial: NCT06006416
Drug: Fenugreek Fibre
RxNorm normalized name: FENUGREEK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 2 x 10g per day with/in food
Trial: NCT06445517
Drug: ISM8207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical formulation: Capsules Mode of Administration: Oral
Trial: NCT05688124
Drug: IBI351
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI351 is administered orally
Trial: NCT05436743
Drug: K-Y Jelly, Topical Gel soaked packs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel used as lubricant
Trial: NCT05844995
Drug: Acetaminophen/Naproxen Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination of acetaminophen/naproxen sodium tablet will be administered orally.
Trial: NCT05560230
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of administered intravenous isotonic saline will be infused over 5-10 min., immediately after intubation
Trial: NCT04815148
Drug: MH004 Ib-1(0.1%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
Trial: NCT04815148
Drug: MH004 Ib-1(0.3%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
Trial: NCT04815148
Drug: MH004 Ib-1(1%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spread approx. 0.5 g of MH004 topical cream to the area of Target AD Lesions.
Trial: NCT04815148
Drug: MH004 Ib-2(0.3%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
Trial: NCT04815148
Drug: MH004 Ib-2(1%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
Trial: NCT04815148
Drug: MH004 Ib-2(3%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spread approx. 0.5 g of MH004 topical cream to the Target Joint.
Trial: NCT06327295
Drug: ATB1651-102- Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 20 weeks with a follow-up for 16 weeks.
Trial: NCT06327295
Drug: ATB1651-102- Cohort 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form- Topical solution; Dosage- 5% formulation The participants will apply the daily dose of 5% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
Trial: NCT06327295
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will receive matching placebo across cohorts 1-4 of the study.
Trial: NCT06520384
Drug: Alcohol 30%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 30% alcohol in 0.25% bupivacaine.
Trial: NCT06520384
Drug: Alcohol 50%
RxNorm normalized name: Isopropyl Alcohol 50% Topical application Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 50% alcohol in 0.25% bupivacaine.
Trial: NCT06520384
Drug: Alcohol 70%
RxNorm normalized name: Alcohol 70% Prep Pads (Medium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive ultrasound-guided injection of each of the three genicular nerves with 0.5-0.75 ml of a solution containing 70% alcohol in 0.25% bupivacaine.
Trial: NCT00002317
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05856136
Drug: Fentanyl Injection
RxNorm normalized name: fentanyl Injection
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Three different fentanyl doses (used for sedation) will be evaluated on their effects on shear wave elastography (SWE) and breathing
Trial: NCT04793022
Drug: Inhaled Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia given with inhaled anesthetics
Trial: NCT06163508
Drug: Q-Cells®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long term observational study of patients who received 1 of 3 different amounts of Q-Cells®.
Trial: NCT05744804
Drug: -group of patients(75 patients) will receive low dose rivaroxaban myocardial infarction plus (acetylsalicylic acid 75 mg and clopidogrel 75 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive low dose rivaroxaban (rivaroxaban 2.5 mg twice daily orally) for 1 month after anterior ST-segment myocardial infarction plus dual antiplatelet therapy (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally)
Trial: NCT05744804
Drug: (acetylsalicylic acid 75 mg once daily orally and clopidogrel 75 mg once daily orally only)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group of patients: 75 Patients of anterior ST-segment myocardial infarction on dual antiplatelet therapy only
Trial: NCT06504290
Drug: VV119 Placebo （in healthy adult subjects）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VV119 0.5 mg Group:2 subjects will receive VV119 Placebo 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:2 subjects will receive VV119 Placebo 1 mg, orally once daily for 14 days.~VV119 2 mg Group:2 subjects will receive VV119 Placebo 2 mg, orally once daily for 14 days.~VV119 4 mg Group:2 subjects will receive VV119 Placebo 4 mg, orally once daily for 14 days.
Trial: NCT06504290
Drug: VV119 （in healthy adult subjects）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VV119 0.5 mg Group:6 subjects will receive VV119 0.5 mg, orally once daily for 14 days.~VV119 1 mg Group:6 subjects will receive VV119 1 mg, orally once daily for 14 days.~VV119 2 mg Group:6 subjects will receive VV119 2 mg, orally once daily for 14 days.~VV119 4 mg Group:6 subjects will receive VV119 4 mg, orally once daily for 14 days.
Trial: NCT06504290
Drug: VV119(in adult patients with schizophrenia)
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VV119 2 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, then take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:6 subjects will receive 2 0.5mgVV119 capsules on the first four days, take 1 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the fifth day to the seventh day , then 2 2mgVV119 capsules and 1 0.5mg VV119 Placebo from the eighth day to the 28th day ,orally once daily.
Trial: NCT05504642
Drug: Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab)
RxNorm normalized name: Chem-Star Recover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In week 1-7, standard administration of concurrent Cisplatin mono 40mg/m2 body surface area d1, 8, 15, 22, 29 (Monday of each treatment week) during radiotherapy. Simultaneous application of Nivolumab 3mg/kg week 1, 3, 5, 7 (on Thursday) and Ipilimumab 1mg/kg in week 5 (on Thursday).
Trial: NCT06504290
Drug: VV119 Placebo （in adult patients with schizophrenia）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VV119 2 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, then take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the 28th day， orally once daily, VV119 4 mg Group:2 subjects will receive 1 0.5mgVV119 capsules and 1 0.5mg VV119 Placebo on the first four days, take 1 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the fifth day to the seventh day , then 2 2mgVV119 Placebo and 1 0.5mg VV119 capsules from the eighth day to the 28th day ,orally once daily.
Trial: NCT05507112
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1650mg/m2/d orally twice-daily, 5 days a week for a total of 5 weeks.
Trial: NCT06503237
Drug: Anti-CD19 CART cells will be given IV at split doses.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split intravenous infusion of Anti-CD19 CART cells of (Dose escalating infusion of 1 - 6 x10\^6 CART cells/kg).
Trial: NCT06175949
Drug: HRS-7085 simulant
RxNorm normalized name: STAPHYLOCOCCUS SIMULANS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD
Trial: NCT06086340
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase Inhibitor Therapy
Trial: NCT04219046
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily
Trial: NCT04927169
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM administration of a volume of saline identical to 10μg/kg CYT107, twice a week for three weeks and up to 7 administrations according to Hospital length of stay
Trial: NCT05302336
Drug: Liposomal doxorubicin + Cyclophosphamide vs Docetaxel + Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients who meet the inclusion criteria must first sign the Informed Consent after learning about the details of the trial, and they can be formally enrolled only when they have completed all the pre-enrollment examinations and are qualified. Recruitment will continue until the planned number of cases is completed. The trial was not terminated until each surviving patient was followed for at least 60 months after treatment ended or when all patients had died. The randomization table was generated by the SAS software program, and the patients were randomly divided into the experimental group (AC liposomal doxorubicin + cyclophosphamide) and the control group (docetaxel + cyclophosphamide).
Trial: NCT05819866
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will match the study drug visually and by taste
Trial: NCT04495608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
Trial: NCT06153758
Drug: Danuglipron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danuglipron oral tablets
Trial: NCT06048484
Drug: Modified FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Oxaliplatin 85 mg per square meter IV~* Irinotecan 150 mg per square meter IV~* Leucovorin 400 mg per square meter IV~* Fluorouracil 2400 mg per square meter IV~* Pegfilgrastim injector kit (6mg subcutaneous)
Trial: NCT05037279
Drug: Bacillus Calmette-Guerin: Strain Russian BCG-I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Induction: 80 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.
Trial: NCT05037279
Drug: Bacillus Calmette-Guerin: Strain TICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Induction: 50 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.
Trial: NCT05373914
Drug: Control: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 250mg tablets (orally)
Trial: NCT06522828
Drug: SSGJ-707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSGJ-707 is a bispecific antibody against human PD-1 and VEGF
Trial: NCT05538663
Drug: Bacillus Calmette Guerin
RxNorm normalized name: BACILLUS CALMETTE-GUERIN,TICE VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravesical once a week for 6 consecutive weeks during induction followed by weekly instillations for 3 consecutive weeks at months 3, 6, 12, 18, 24, 30, and 36 months
Trial: NCT05254184
Drug: Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administering the KRAS peptide vaccine with poly-ICLC adjuvant in combination with nivolumab and ipilimumab
Trial: NCT06333964
Drug: AST-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-001, PO bid for 24weeks (dosage according to weight range)
Trial: NCT06333964
Drug: Placebo of AST-001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo of AST-001, PO bid for 12 weeks + AST-001, PO bid for 12 weeks (dosage according to weight range)
Trial: NCT06480968
Drug: CTH120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIH-CTH120-SAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a single administration of CTH120 or placebo. Four consecutive dose levels (20 mg/day, 40 mg/day, 85 mg/day and 160 mg/day) are planned. If no significant clinical adverse events are observed in the FIH-CTH120-SAD phase, an additional 5th cohort will be recruited to conduct the 5th dose level.~FIH-CTH120-MAD: Each independent cohort of 8 subjects (placebo=2 and CTH120=6 per dose) will receive a daily administration of CTH120 or placebo for 7 days. Three consecutive dose levels are planned. The starting dose will be confirmed following the observed results of FIH-CTH120-SAD.~FIH-CTH120-FI: One dosage of CTH120 will be assessed in 12 healthy male and female subjects in two conditions (Fed and Fasting). Subjects will be randomly assigned to 2 sequences: 6 subjects in a sequence fed then fasting condition, 6 subjects in the reverse sequence (fasting, then fed condition).
Trial: NCT05473923
Drug: Receiving chemotherapeutic or targeted drugs recommended by molecular tumor board.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with FDA-approved chemotherapeutic or targeted drugs which were recommended by the molecular tumor board (MTB), based on their expertise, patients willingness as well as evidences from PTCs-drug screening and bioinformatic prediction for drug response.
Trial: NCT04366115
Drug: AVM0703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion at 10 mg/mL in normal saline over 1 hour to patients.
Trial: NCT04366115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion in normal saline over 1 hour to patients.
Trial: NCT04595682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will attend two identical laboratory sessions to test sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol, once during the early follicular phase and once during the late follicular phase. The test battery consists of measures of rewarding effects and alcohol (or placebo) effects on disinhibition and impulsive choice. The placebo consists of 300 ml of lemon-flavored soda with a small amount (3 ml) of alcohol floated on top.
Trial: NCT06145308
Drug: larotinib or enttraitinib
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma (NTRK gene fusion or mutant group) : NTRK inhibitors such as larotinib 100mg Bid po or enttraitinib 600mg qd po; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing (NTRK gene fusion or mutant group) : NTRK inhibitors such as larotinib 100mg Bid po or enttraitinib 600mg qd po;
Trial: NCT06145308
Drug: antiandrogen drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant and translational studies in patients with locally advanced/recurrent and advanced oligometastatic salivary gland carcinoma(AR positive group) : leprerelin 3.75mg subcutaneous injection Q4w+ bicalutamide 80mg qd po ± Abiraterone 1000mg po qdor antiandrogen drug treatment; Rescue therapy for locally advanced/recurrent or distant metastatic salivary gland carcinoma that cannot tolerate or refuse surgery and is rapidly progressing(AR positive group) : leprerelin 3.75mg subcutaneous injection Q4w+ bicalutamide 80mg qd po or antiandrogen drug treatment;
Trial: NCT06145308
Drug: HR-positive group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abesili 150mg bid po or Piperoxili 125mg qd po, etc CDK4/6 inhibitors + aromatase inhibitors (letrozole 2.5mg qd po or anastrozole 1mg qd po or Exemestane 20mg qd po) or Fluvis Group 0.5mg im q4w;
Trial: NCT06145308
Drug: PI3K mutant group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PI3K inhibitors such as Apelis 300mg qd po + Fluvis group 0.5mg im q4w, etc
Trial: NCT06145308
Drug: Homologous Recombination repair defect group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olapalil 300mg bid po or Nilapalil 300mgPARP inhibitors such as qd po or fluzopalil 150mg bid po or pamipalil 60mg bid po;
Trial: NCT06145308
Drug: Apalolito vorellizumab group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apalolito vorellizumab 5mg/kg+ Platinum dual drug (white purple 260mg/m2 Q3w/ Paclitaxel liposome 175mg/m2/ Docetaxel 75mg/m2/ vinorelbine 25mg/m2 + cisplatin 75mg/m2, Q3w or carboplatin 350mg/m2 q3w) + bevacizumab 5mg/kg;
Trial: NCT05480111
Drug: Sham Local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mls of normal saline given at incision site
Trial: NCT06110338
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo iv. once.
Trial: NCT06110338
Drug: IBI355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI355 iv. once.